logo

INDOCO vs LUPIN: Stock Comparison

INDOCO REMEDIES vs LUPINUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

LUPIN is the larger company by market capitalisation. LUPIN shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

INDOCO leads 1; LUPIN leads 10 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

INDOCOLUPIN

Valuation lens

What price are you paying?

Market CapContext only
₹2,077 Cr
₹88,166 Cr
P/E RatioLUPIN has the lower reading
368.85x
15.94x ✓
P/B RatioINDOCO has the lower reading
2.21x ✓
3.93x
EPSLUPIN has the higher reading
₹7.04
₹30.95 ✓
Book ValueContext only
₹100.98
₹492.38
Dividend YieldLUPIN has the higher reading
0.09%
0.92% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
LUPIN is the larger company
₹88,166 Cr vs ₹2,077 Cr
P/E Ratio
LUPIN has a lower P/E
15.94x vs 368.85x
P/B Ratio
INDOCO has a lower P/B
2.21x vs 3.93x
EPS
LUPIN has higher earnings per share
₹30.95 vs ₹7.04
Dividend Yield
LUPIN has a higher dividend yield
0.92% vs 0.09%
Revenue Growth (TTM YoY)
LUPIN has faster revenue growth
31.9% vs 21.9%
EPS Growth (TTM YoY)
LUPIN has faster EPS growth
89% vs 0%
ROE
LUPIN has a higher ROE
23.79% vs -0.51%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricINDOCOLUPIN
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricINDOCOLUPIN
Live Price₹225.6₹1,922
Day Change-2.55%-2.14%
Volume1.07 L7.29 L
52-Week High₹291₹2,529.5
52-Week Low₹162.19₹1,900
Distance from 52W High-22.47%-24.02%

Valuation

MetricINDOCOLUPIN
Market Cap₹2,077 Cr₹88,166 Cr
P/E Ratio368.85x15.94x
P/B Ratio2.21x3.93x
EPS₹7.04₹30.95
Book Value₹100.98₹492.38
Dividend Yield0.09%0.92%

Growth

MetricINDOCOLUPIN
Revenue Growth (TTM YoY)21.9%31.9%
EPS Growth (TTM YoY)0%89%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricINDOCOLUPIN
ROE-0.51%23.79%
ROCE4.26%22.95%
Net Margin-5.31%17.65%
Operating Margin4.57%26.14%
Debt to Equity0.64x0.26x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricINDOCOLUPIN
Promoter Holding58.86%46.57%
FII Holding1.27%▲ 0.33 pp22.42%▲ 0.71 pp
DII Holding17.68%▼ 0.47 pp24.65%▼ 0.67 pp
Public Holding22.04%▲ 0.14 pp6.08%▼ 0.03 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: INDOCO REMEDIES and LUPIN.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.